Is the Speed of Biosimilar Penetration Related to Demand-Side Polices?
Author(s)
Han H1, Kim M2, Choi E1, Song Y3, Shin G2, Bae S2
1Ewha Womans University, Seoul, Republic of Korea, 41, South Korea, 2Ewha Womans University, Seoul, Korea, Republic of (South), 3Ewha Womans University, Seoul, South Korea
Presentation Documents
OBJECTIVES: Market penetration of biosimilars is closely linked to the speed at which they are penetrated, influenced by factors like policies, perceptions, and pricing. Specifically, we sought to identify the correlation between speed and demand-side policies in 8 high-income countries (France, Germany, Italy, Japan, Korea, Spain, Sweden, and the UK).
METHODS: Infliximab, Rituximab, and Trastuzumab were selected because their biosimilars have been launched with varying availability since 2018. Using the IQVIA-MIDAS® database, we identified the crossover points for each biologics where biosimilar sales surpassed the originals’ and analyzed the average time in quarters (Q). The entry point (0Q) was set to reflect different biosimilar introduction timings in each country. The observation period varied for each biologics, based on the country where the respective biosimilar was released last (Infliximab: 21Q, Rituximab: 9Q, Trastuzumab: 7Q). Countries were classified by the number of biologics achieving crossover and the time taken. We analyzed the correlation between the penetration speed of biosimilars and demand-side policies by examining the number of implemented policies out of five: financial-incentives, prescribing guidelines, prescription budgets, prescription quotas, and education.
RESULTS: Countries were classified into three groups based on the biologics that achieved market crossover: a group with all 3-biologicss crossed (High, Middle), a group with 0-1 biologics crossed (Low). High and Middle groups were divided by the median time to cross (5Q), which ranged from the fastest 3.67Q (The UK) to the slowest 8.33Q (Spain). High group (Italy, Sweden, and the UK) implemented four or more demand-side policies, while Middle group (France, Spain) had only two or less. In low group (Germany, Japan, and Korea), most countries (Japan, Korea) had no policies.
CONCLUSIONS: Countries with prompt biosimilar market penetration implemented robust demand-side policies, whereas those with slow penetration exhibited the opposite trend. This underscores the importance of demand-side policies in enhancing biosimilar penetration speed.
Conference/Value in Health Info
Value in Health, Volume 27, Issue 12, S2 (December 2024)
Code
HPR120
Topic
Health Policy & Regulatory
Topic Subcategory
Pricing Policy & Schemes, Public Spending & National Health Expenditures, Reimbursement & Access Policy
Disease
Biologics & Biosimilars, Gastrointestinal Disorders, Oncology